Cantor Fitzgerald Issues Negative Estimate for TVTX Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at Cantor Fitzgerald cut their FY2026 earnings per share estimates for Travere Therapeutics in a research note issued on Friday, October 31st. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will earn $0.91 per share for the year, down from their prior estimate of $1.00. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Several other research analysts have also recently issued reports on TVTX. HC Wainwright reissued a “buy” rating and issued a $47.00 target price on shares of Travere Therapeutics in a research report on Friday, September 19th. Citigroup raised their target price on Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday. Stifel Nicolaus raised their price objective on Travere Therapeutics from $20.00 to $25.00 and gave the stock a “hold” rating in a research note on Friday, September 12th. Wall Street Zen raised Travere Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, October 4th. Finally, Wells Fargo & Company raised their price objective on Travere Therapeutics from $27.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.79.

Travere Therapeutics Trading Up 18.6%

Shares of NASDAQ:TVTX opened at $35.16 on Monday. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of -17.24 and a beta of 0.83. The company has a debt-to-equity ratio of 9.50, a quick ratio of 1.98 and a current ratio of 2.00. The stock’s 50-day simple moving average is $24.50 and its two-hundred day simple moving average is $19.41. Travere Therapeutics has a 52-week low of $12.91 and a 52-week high of $35.34.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%.The company had revenue of $113.15 million for the quarter, compared to analysts’ expectations of $106.09 million. During the same period last year, the firm posted ($0.70) earnings per share. Travere Therapeutics’s revenue was up 162.1% compared to the same quarter last year.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently bought and sold shares of TVTX. Wealth Enhancement Advisory Services LLC bought a new stake in Travere Therapeutics during the 1st quarter valued at $182,000. KBC Group NV bought a new stake in Travere Therapeutics during the 1st quarter valued at $75,000. Bank of New York Mellon Corp raised its position in Travere Therapeutics by 7.9% during the 1st quarter. Bank of New York Mellon Corp now owns 233,942 shares of the company’s stock valued at $4,192,000 after purchasing an additional 17,079 shares in the last quarter. Penserra Capital Management LLC bought a new stake in Travere Therapeutics during the 1st quarter valued at $1,962,000. Finally, Cerity Partners LLC bought a new stake in Travere Therapeutics during the 1st quarter valued at $217,000.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Peter Heerma sold 2,662 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $30.00, for a total transaction of $79,860.00. Following the completion of the transaction, the insider owned 124,662 shares in the company, valued at $3,739,860. This trade represents a 2.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Elizabeth E. Reed sold 10,000 shares of Travere Therapeutics stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the transaction, the insider owned 89,878 shares of the company’s stock, valued at approximately $2,246,950. This trade represents a 10.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 133,235 shares of company stock worth $3,979,015 in the last quarter. 4.19% of the stock is owned by corporate insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.